GlassScriptPhysician profile
Kshama Keshava Bhat
NPI 1255526190
$4,247.17
in general payments reported to CMS, 2019-2025
28 companies · $1,064 in 2025
The $1,064 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $98.87 · 2021: $371 · 2022: $895 · 2023: $897 · 2024: $921 · 2025: $1,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,850 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,849.61 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,903.43 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $604.64 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $375.01 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $205.50 | 2022-2025 | |
| Pfizer INC. | $190.30 | 2022-2025 | |
| Exact Sciences Corporation | $179.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $105.89 | 2023-2024 | |
| Convatec INC. | $89.22 | 2022 | |
| Abbott Laboratories | $70.50 | 2022-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $66.84 | 2023-2024 | Veozah |
| Glaxosmithkline, LLC. | $56.94 | 2024-2025 | Shingrix, Arexvy |
| Almatica Pharma LLC | $49.78 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $38.18 | 2022-2023 | Prehevbrio |
| Esperion Therapeutics, INC. | $32.95 | 2024 | Nexletol |
| Merck Sharp & Dohme LLC | $32.83 | 2025 | Gardasil 9, Capvaxive, Vaxneuvance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $28.61 | 2024 | Ibsrela |
| Daiichi Sankyo INC. | $27.97 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $22.72 | 2025 | Baqsimi |
| Otsuka America Pharmaceutical, INC. | $19.87 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.70 | 2022 | |
| Endo Pharmaceuticals INC. | $18.40 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $18.02 | 2024 | Imcivree |
| Ultragenyx Pharmaceutical INC. | $17.47 | 2022 | |
| Currax Pharmaceuticals LLC | $15.91 | 2025 | Contrave |
| Sanofi Pasteur INC. | $15.56 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.18 | 2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.67 | 2023 | Xifaxan |
| Amgen INC. | $13.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kshama Keshava Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.